Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

novel modalities

- PMLiVE

CGT Catapult establishes industry safety consortium for cell therapies

A universal safety test for CGTs could reduce both costs and wait times for treatment

- PMLiVE

Merck KGaA given FDA Fast Track designation for generalised myasthenia gravis drug

Cladribine capsules could become the first ever oral treatment for gMG

- PMLiVE

Moderna shares positive phase 3 results for mRNA flu vaccine candidate

More than 600,000 people in the US were hospitalised due to flu-related illness last year

- PMLiVE

BioNTech expands mRNA capabilities with $1.25bn CureVac acquisition

The deal will support the advancement of BioNTech’s mRNA-based cancer immunotherapies

- PMLiVE

Merck KGaA expands rare tumour portfolio with $3.9bn SpringWorks acquisition

SpringWorks’ Gomekli was approved by the FDA earlier this year to treat patients with NF1

- PMLiVE

Merck KGaA’s Mavenclad tablets recommended by NICE for wider MS use

The neurological disorder affects more than 150,000 people in the UK

- PMLiVE

Boehringer gains access to Synaffix’s ADC technology through $1.3bn licensing deal

The Lonza company will provide access to its ADC technologies for an undisclosed number of targets

- PMLiVE

GSK gains exclusive option on DualityBio’s preclinical ADC in deal worth over $1bn

The candidate leverages DualityBio's platform against a gastrointestinal cancer target

- PMLiVE

Merck KGaA/Abbisko share positive phase 3 results for pimicotinib in rare tumour type

The companies entered into a licensing agreement for the candidate in December last year

- PMLiVE

GSK and CureVac restructure current mRNA collaboration in deal worth over €1.4bn

The companies have been working together to develop mRNA vaccines for infectious diseases since 2020

- PMLiVE

Moderna’s RSV vaccine mRESVIA granted FDA approval for use in older adults

The approval marks the first time an mRNA vaccine has been approved for a disease other than COVID-19

- PMLiVE

Merck KGaA signs definitive agreement to acquire Mirus Bio in deal worth $600m

The deal aims to advance Merck’s viral vector manufacturing of cell and gene therapies

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links